Base de dados : MEDLINE
Pesquisa : D02.540.576.500.999 [Categoria DeCS]
Referências encontradas : 1699 [refinar]
Mostrando: 1 .. 10   no formato [Detalhado]

página 1 de 170 ir para página                         

  1 / 1699 MEDLINE  
              next record last record
seleciona
para imprimir
Fotocópia
Texto completo
Texto completo
[PMID]:29226307
[Au] Autor:Romero L; Huerfano C; Grillo-Ardila CF
[Ad] Endereço:Department of Obstetrics and Gynecology, Faculty of Medicine, Universidad Nacional de Colombia, Bogota, Colombia.
[Ti] Título:Macrolides for treatment of Haemophilus ducreyi infection in sexually active adults.
[So] Source:Cochrane Database Syst Rev;12:CD012492, 2017 Dec 11.
[Is] ISSN:1469-493X
[Cp] País de publicação:England
[La] Idioma:eng
[Ab] Resumo:BACKGROUND: Chancroid is a genital ulcerative disease caused by Haemophilus ducreyi. This microorganism is endemic in Africa, where it can cause up to 10% of genital ulcers. Macrolides may be an effective alternative to treat chancroid and, based on their oral administration and duration of therapy, could be considered as first line therapy. OBJECTIVES: To assess the effectiveness and safety of macrolides for treatment of H ducreyi infection in sexually active adults. SEARCH METHODS: We searched the Cochrane STI Group Specialized Register, CENTRAL, MEDLINE, Embase, LILACS, WHO ICTRP, ClinicalTrials.gov and Web of Science to 30 October 2017. We also handsearched conference proceedings and reference lists of retrieved studies. SELECTION CRITERIA: Randomized controlled trials (RCTs) comparing macrolides in different regimens or with other therapeutic alternatives for chancroid. DATA COLLECTION AND ANALYSIS: Two review authors independently assessed trials for inclusion, extracted data and assessed risk of bias. We resolved disagreements through consensus. We used the GRADE approach to assess the quality of the evidence. MAIN RESULTS: Seven RCTs (875 participants) met our inclusion criteria, of which four were funded by industry. Five studies (664 participants) compared macrolides with ceftriaxone, ciprofloxacin, spectinomycin or thiamphenicol. Low quality evidence suggested there was no difference between the groups after treatment in terms of clinical cure (risk ratio (RR) 1.09, 95% confidence interval (CI) 0.97 to 1.21; 2 studies, 340 participants with syndromic approach and RR 1.06, 95% CI 0.98 to 1.15; 5 studies, 348 participants with aetiological diagnosis) or improvement (RR 0.89, 95% CI 0.52 to 1.52; 2 studies, 340 participants with syndromic approach and RR 0.80, 95% CI 0.42 to 1.51; 3 studies, 187 participants with aetiological diagnosis). Based on low and very low quality evidence, there was no difference between macrolides and any other antibiotic treatments for microbiological cure (RR 0.93, 95% CI 0.74 to 1.16; 1 study, 45 participants) and minor adverse effects (RR 1.34, 95% CI 0.24 to 7.51; 3 studies, 412 participants).Two trials (269 participants) compared erythromycin with any other macrolide type. Low quality evidence suggested that, compared with azithromycin or rosaramicin, long courses of erythromycin did not increase clinical cure (RR 1.00, 95% CI 0.91 to 1.10; 2 studies, 269 participants with syndromic approach and RR 1.04, 95% CI 0.93 to 1.16; 2 studies, 211 participants with aetiological diagnosis), with a similar frequency of minor adverse effects between the groups (RR 1.14, 95% CI 0.63 to 2.06; 1 trial, 101 participants). For this comparison, subgroup analysis found no difference between HIV-positive participants (RR 1.02, 95% CI 0.73 to 1.43; 1 study, 38 participants) and HIV-negative participants (RR 1.04, 95% CI 0.94 to 1.14; 1 study, 89 participants). We downgraded the quality of evidence to low, because of imprecision, some limitations on risk of bias and heterogeneity.None of the trials reported serious adverse events, cost effectiveness and participant satisfaction. AUTHORS' CONCLUSIONS: At present, the quality of the evidence on the effectiveness and safety of macrolides for treatment of H ducreyi infection in sexually active adults is low, implying that we are uncertain about the estimated treatment effect. There is no statistically significant difference between the available therapeutic alternatives for the treatment of sexually active adults with genital ulcers compatible with chancroid. Low quality evidence suggests that azithromycin could be considered as the first therapeutic alternative, based on their mono-dose oral administration, with a similar safety and effectiveness profile, when it is compared with long-term erythromycin use.Due to sparse available evidence about the safety and effectiveness of macrolides to treat H ducreyi infection in people with HIV, these results should be taken with caution.
[Mh] Termos MeSH primário: Antibacterianos/uso terapêutico
Cancroide/tratamento farmacológico
Haemophilus ducreyi
Macrolídeos/uso terapêutico
[Mh] Termos MeSH secundário: Adolescente
Adulto
Azitromicina/uso terapêutico
Eritromicina/efeitos adversos
Eritromicina/uso terapêutico
Seres Humanos
Leucomicinas/uso terapêutico
Macrolídeos/efeitos adversos
Meia-Idade
Ensaios Clínicos Controlados Aleatórios como Assunto
Resultado do Tratamento
[Pt] Tipo de publicação:JOURNAL ARTICLE; META-ANALYSIS; REVIEW
[Nm] Nome de substância:
0 (Anti-Bacterial Agents); 0 (Leucomycins); 0 (Macrolides); 63937KV33D (Erythromycin); 83905-01-5 (Azithromycin); E907BNQ7SH (rosaramicin)
[Em] Mês de entrada:1801
[Cu] Atualização por classe:180123
[Lr] Data última revisão:
180123
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:171212
[St] Status:MEDLINE
[do] DOI:10.1002/14651858.CD012492.pub2


  2 / 1699 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:28559578
[Au] Autor:Sugawara A; Maruyama H; Shibusawa S; Matsui H; Hirose T; Tsutsui A; Froyman R; Ludwig C; Koebberling J; Hanaki H; Kleefeld G; Omura S; Sunazuka T
[Ad] Endereço:Kitasato Institute for Life Sciences and Graduate School of Infection Control Sciences, Kitasato University, Tokyo, Japan.
[Ti] Título:5-O-Mycaminosyltylonolide antibacterial derivatives: design, synthesis and bioactivity.
[So] Source:J Antibiot (Tokyo);70(8):878-887, 2017 Jul.
[Is] ISSN:0021-8820
[Cp] País de publicação:Japan
[La] Idioma:eng
[Ab] Resumo:Tylosin is a 16-membered macrolide broad-spectrum antibiotic that has an important role in veterinary medicine, active against Gram-positive and a restricted range of Gram-negative bacteria. We synthesized 15 types of tylosin-related derivatives by chemical modification and evaluated them against mastitis pathogens. Among them, 20-deoxy-20-{N-methyl-N-[1-(3-quinolyl)-1H-1,2,3-triazol-4-yl]methylamino}-5-O-mycaminosyltylonolide 2f and 20-deoxy-20-{N-benzyl-N-[1-(3-quinolyl)-1H-1,2,3-triazol-4-yl]methylamino}-5-O-mycaminosyltylonolide 2k were found to not only expand their antibacterial impact to include Gram-negative bacteria, such as Escherichia coli and Klebsiella pneumoniae, but also to retain or increase antibacterial activity against Gram-positive bacteria, such as Staphylococcus aureus and Streptococcus uberis in comparison with the parent tylosin.
[Mh] Termos MeSH primário: Antibacterianos/farmacologia
Bactérias Gram-Negativas/efeitos dos fármacos
Bactérias Gram-Positivas/efeitos dos fármacos
Leucomicinas/farmacologia
[Mh] Termos MeSH secundário: Antibacterianos/síntese química
Antibacterianos/química
Leucomicinas/síntese química
Leucomicinas/química
Tilosina/farmacologia
[Pt] Tipo de publicação:COMPARATIVE STUDY; JOURNAL ARTICLE
[Nm] Nome de substância:
0 (Anti-Bacterial Agents); 0 (Leucomycins); 61257-02-1 (mycaminosyltylonolide); YEF4JXN031 (Tylosin)
[Em] Mês de entrada:1708
[Cu] Atualização por classe:170808
[Lr] Data última revisão:
170808
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:170601
[St] Status:MEDLINE
[do] DOI:10.1038/ja.2017.61


  3 / 1699 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:27453999
[Au] Autor:Kim E; Song MC; Kim MS; Beom JY; Lee EY; Kim DM; Nam SJ; Yoon YJ
[Ad] Endereço:Department of Chemistry and Nanoscience, Ewha Womans University , Seoul 03760, Republic of Korea.
[Ti] Título:Characterization of the Two Methylation Steps Involved in the Biosynthesis of Mycinose in Tylosin.
[So] Source:J Nat Prod;79(8):2014-21, 2016 Aug 26.
[Is] ISSN:1520-6025
[Cp] País de publicação:United States
[La] Idioma:eng
[Ab] Resumo:The S-adenosyl-l-methionine-dependent O-methyltransferases TylE and TylF catalyze the last two methylation reactions in the tylosin biosynthetic pathway of Streptomyces fradiae. It has long been known that the TylE-catalyzed C2‴-O-methylation of the 6-deoxy-d-allose bound to demethylmacrocin or demethyllactenocin precedes the TylF-catalyzed C3‴-O-methylation of the d-javose (C2‴-O-methylated 6-deoxy-d-allose) attached to macrocin or lactenocin. This study reveals the unexpected substrate promiscuity of TylE and TylF responsible for the biosynthesis of d-mycinose (C3‴-O-methylated d-javose) in tylosin through the identification of a new minor intermediate 2‴-O-demethyldesmycosin (2; 3‴-methyl-demethyllactenocin), which lacks a 2‴-O-methyl group on the mycinose moiety of desmycosin, along with 2‴-O-demethyltylosin (1; 3‴-methyl-demethylmacrocin) that was previously detected from the S. fradiae mutant containing a mutation in the tylE gene. These results unveil the unique substrate flexibility of TylE and TylF and demonstrate their potential for the engineered biosynthesis of novel glycosylated macrolide derivatives.
[Mh] Termos MeSH primário: Hexoses/biossíntese
Metiltransferases/metabolismo
Streptomyces/enzimologia
Tilosina/metabolismo
[Mh] Termos MeSH secundário: Antibacterianos/metabolismo
Hexoses/química
Leucomicinas/metabolismo
Metilação
Estrutura Molecular
Mutação
S-Adenosilmetionina/metabolismo
Streptomyces/genética
Tilosina/análogos & derivados
[Pt] Tipo de publicação:JOURNAL ARTICLE
[Nm] Nome de substância:
0 (Anti-Bacterial Agents); 0 (D-mycinose); 0 (Hexoses); 0 (Leucomycins); 11032-98-7 (tylosin B); 11049-15-3 (macrocin); 7LP2MPO46S (S-Adenosylmethionine); EC 2.1.1.- (Methyltransferases); YEF4JXN031 (Tylosin)
[Em] Mês de entrada:1705
[Cu] Atualização por classe:170502
[Lr] Data última revisão:
170502
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:160726
[St] Status:MEDLINE
[do] DOI:10.1021/acs.jnatprod.6b00267


  4 / 1699 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
PubMed Central Texto completo
Texto completo
[PMID]:25930739
[Au] Autor:Awakawa T; Crüsemann M; Munguia J; Ziemert N; Nizet V; Fenical W; Moore BS
[Ad] Endereço:Center of Marine Biotechnology and Biomedicine, Scripps Institution of Oceanography, University of California at San Diego, 9500 Gilman Drive, La Jolla, CA 92093-0204 (USA).
[Ti] Título:Salinipyrone and Pacificanone Are Biosynthetic By-products of the Rosamicin Polyketide Synthase.
[So] Source:Chembiochem;16(10):1443-7, 2015 Jul 06.
[Is] ISSN:1439-7633
[Cp] País de publicação:Germany
[La] Idioma:eng
[Ab] Resumo:Salinipyrones and pacificanones are structurally related polyketides from Salinispora pacifica CNS-237 that are proposed to arise from the same modular polyketide synthase (PKS) assembly line. Genome sequencing revealed a large macrolide PKS gene cluster that codes for the biosynthesis of rosamicin A and a series of new macrolide antibiotics. Mutagenesis experiments unexpectedly correlated salinipyrone and pacificanone biosynthesis to the rosamicin octamodule Spr PKS. Remarkably, this bifurcated polyketide pathway illuminates a series of enzymatic domain- and module-skipping reactions that give rise to natural polyketide product diversity. Our findings enlarge the growing knowledge of polyketide biochemistry and illuminate potential challenges in PKS bioengineering.
[Mh] Termos MeSH primário: Actinobacteria/enzimologia
Antibacterianos/metabolismo
Cicloexanonas/metabolismo
Leucomicinas/metabolismo
Policetídeo Sintases/metabolismo
Pironas/metabolismo
[Mh] Termos MeSH secundário: Actinobacteria/genética
Actinobacteria/metabolismo
Sequência de Aminoácidos
Vias Biossintéticas
Dados de Sequência Molecular
Família Multigênica
Mutagênese
Policetídeo Sintases/química
Policetídeo Sintases/genética
[Pt] Tipo de publicação:JOURNAL ARTICLE; RESEARCH SUPPORT, N.I.H., EXTRAMURAL; RESEARCH SUPPORT, NON-U.S. GOV'T
[Nm] Nome de substância:
0 (Anti-Bacterial Agents); 0 (Cyclohexanones); 0 (Leucomycins); 0 (Pyrones); 0 (pacificanone A); 0 (salinipyrone A); 79956-01-7 (Polyketide Synthases); E907BNQ7SH (rosaramicin)
[Em] Mês de entrada:1603
[Cu] Atualização por classe:161208
[Lr] Data última revisão:
161208
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:150502
[St] Status:MEDLINE
[do] DOI:10.1002/cbic.201500177


  5 / 1699 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:25047182
[Au] Autor:Iizaka Y; Higashi N; Li W; Fukumoto A; Anzai Y; Kato F
[Ad] Endereço:Faculty of Pharmaceutical Sciences, Toho University, 2-2-1 Miyama, Funabashi, Chiba, 274-8510, Japan.
[Ti] Título:A new mycinosyl rosamicin derivative produced by an engineered Micromonospora rosaria mutant with a cytochrome P450 gene disruption introducing the D-mycinose biosynthetic gene.
[So] Source:J Ind Microbiol Biotechnol;41(9):1451-6, 2014 Sep.
[Is] ISSN:1476-5535
[Cp] País de publicação:Germany
[La] Idioma:eng
[Ab] Resumo:Genetic engineering of post-polyketide synthase-tailoring genes can be used to generate new macrolide analogs through manipulation of the genes involved in their biosynthesis. Rosamicin, a 16-member macrolide antibiotic produced by Micromonospora rosaria IFO13697, contains a formyl group and an epoxide at C-20 and C-12/13 positions which are formed by the cytochrome P450 enzymes RosC and RosD, respectively. The D-mycinose biosynthesis genes in mycinamicin II biosynthesis gene cluster of Micomonospora guriseorubida A11725 were introduced into the rosC and rosD disruption mutants of M. rosaria IFO13697. The resulting engineered strains, M. rosaria TPMA0054 and TPMA0069, produced mycinosyl rosamicin derivatives, IZIV and IZV, respectively. IZIV was identified as a novel mycinosyl rosamicin derivative, 23-O-mycinosyl-20-deoxo-20-dihydrorosamicin.
[Mh] Termos MeSH primário: Antibacterianos/biossíntese
Proteínas de Bactérias/genética
Sistema Enzimático do Citocromo P-450/genética
Leucomicinas/biossíntese
Micromonospora/genética
Micromonospora/metabolismo
[Mh] Termos MeSH secundário: Antibacterianos/química
Proteínas de Bactérias/metabolismo
Vias Biossintéticas
Sistema Enzimático do Citocromo P-450/metabolismo
Engenharia Genética
Leucomicinas/química
Micromonospora/enzimologia
Estrutura Molecular
Mutação
Policetídeo Sintases/genética
[Pt] Tipo de publicação:JOURNAL ARTICLE
[Nm] Nome de substância:
0 (Anti-Bacterial Agents); 0 (Bacterial Proteins); 0 (Leucomycins); 79956-01-7 (Polyketide Synthases); 9035-51-2 (Cytochrome P-450 Enzyme System); E907BNQ7SH (rosaramicin)
[Em] Mês de entrada:1412
[Cu] Atualização por classe:171014
[Lr] Data última revisão:
171014
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:140723
[St] Status:MEDLINE
[do] DOI:10.1007/s10295-014-1488-2


  6 / 1699 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:24556631
[Au] Autor:Poachanukoon O; Koontongkaew S; Monthanapisut P; Pattanacharoenchai N
[Ad] Endereço:Medicinal Herb Research Unit for Asthma, Faculty of Medicine, Thammasat University, Pathum Thani, Thailand.
[Ti] Título:Macrolides attenuate phorbol ester-induced tumor necrosis factor-α and mucin production from human airway epithelial cells.
[So] Source:Pharmacology;93(1-2):92-9, 2014.
[Is] ISSN:1423-0313
[Cp] País de publicação:Switzerland
[La] Idioma:eng
[Ab] Resumo:BACKGROUND/AIMS: Macrolide antibiotics are effective drugs in chronic bronchiolitis and chronic rhinosinusitis with mucus hypersecretion. However, the mechanism of action is unclear. This study was designed to investigate the effect of azithromycin (AZM; 15-membered) and midecamycin acetate (MDM; 16-membered) on MUC5AC and MUC2 gene expression and secretion from human airway epithelial cells. The effects of the two macrolides on tumor necrosis factor-α (TNF-α) release were also examined. METHODS: Confluent NCI-H292 human mucoepidermoid airways epithelial cells were pretreated with AZM or MDM for 2 h and then stimulated with 200 nmol/l phorbol 12-myristate 13-acetate (PMA) for 8 h. The MUC5AC and MUC2 gene expression was measured by real-time quantitative RT-PCR. Total mucin in culture supernatants was measured using enzyme-linked lectin assay. Enzyme-linked immunosorbent assay was used to determine MUC5AC, MUC2 and TNF-α released by the cells. RESULTS: AZM and MDM attenuated PMA-induced MUC5AC and MUC2 gene and protein expression in NCI-H292 cells. They also suppressed PMA-mediated TNF-α in the cells. CONCLUSION: The present study demonstrates that AZM and MDM suppress the synthesis of mucin and TNF-α from human airway epithelial cells.
[Mh] Termos MeSH primário: Antibacterianos/farmacologia
Azitromicina/farmacologia
Leucomicinas/farmacologia
Mucina-5AC/metabolismo
Mucina-2/metabolismo
Fator de Necrose Tumoral alfa/metabolismo
[Mh] Termos MeSH secundário: Linhagem Celular Tumoral
Sobrevivência Celular/efeitos dos fármacos
Células Epiteliais/metabolismo
Regulação da Expressão Gênica/efeitos dos fármacos
Seres Humanos
Mucina-5AC/genética
Mucina-2/genética
Ésteres de Forbol
Sistema Respiratório/citologia
[Pt] Tipo de publicação:JOURNAL ARTICLE; RESEARCH SUPPORT, NON-U.S. GOV'T
[Nm] Nome de substância:
0 (Anti-Bacterial Agents); 0 (Leucomycins); 0 (MUC2 protein, human); 0 (MUC5AC protein, human); 0 (Mucin 5AC); 0 (Mucin-2); 0 (Phorbol Esters); 0 (Tumor Necrosis Factor-alpha); 20839-06-9 (phorbol-12-myristate); 83905-01-5 (Azithromycin); N34Z0Y5UH7 (midecamycin)
[Em] Mês de entrada:1411
[Cu] Atualização por classe:171116
[Lr] Data última revisão:
171116
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:140222
[St] Status:MEDLINE
[do] DOI:10.1159/000358366


  7 / 1699 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
[PMID]:24064918
[Au] Autor:Huong NL; Hoang NH; Shrestha A; Sohng JK; Yoon YJ; Park JW
[Ad] Endereço:Department of Pharmaceutical Engineering, SunMoon University, Asan 336-708, Republic of Korea.
[Ti] Título:Biotransformation of rosamicin antibiotic into 10,11-dihydrorosamicin with enhanced in vitro antibacterial activity against MRSA.
[So] Source:J Microbiol Biotechnol;24(1):44-7, 2014 Jan.
[Is] ISSN:1738-8872
[Cp] País de publicação:Korea (South)
[La] Idioma:eng
[Ab] Resumo:A biotransformation approach using microbes as biocatalysts can be an efficient tool for the targeted modification of existing antibiotic chemical scaffolds to create previously uncharacterized therapeutic agents. By employing a recombinant Streptomyces venezuelae strain as a microbial catalyst, a reduced macrolide, 10,11-dihydrorosamicin, was created from rosamicin macrolide. Its chemical structure was spectroscopically elucidated, and the new rosamicin analog showed 2-4-fold higher antibacterial activity against two strains of methicillin-resistant Staphylococcus aureus compared with its parent rosamicin. This kind of biocatalytic approach is able to expand existing antibiotic entities and can also provide more diverse therapeutic resources.
[Mh] Termos MeSH primário: Antibacterianos/metabolismo
Antibacterianos/farmacologia
Leucomicinas/metabolismo
Leucomicinas/farmacologia
Staphylococcus aureus Resistente à Meticilina/efeitos dos fármacos
Streptomyces/metabolismo
[Mh] Termos MeSH secundário: Antibacterianos/química
Biotransformação
Leucomicinas/química
Macrolídeos/metabolismo
Macrolídeos/farmacologia
Testes de Sensibilidade Microbiana
Análise Espectral
[Pt] Tipo de publicação:JOURNAL ARTICLE; RESEARCH SUPPORT, NON-U.S. GOV'T
[Nm] Nome de substância:
0 (Anti-Bacterial Agents); 0 (Leucomycins); 0 (Macrolides); E907BNQ7SH (rosaramicin)
[Em] Mês de entrada:1409
[Cu] Atualização por classe:141120
[Lr] Data última revisão:
141120
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:130926
[St] Status:MEDLINE


  8 / 1699 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
[PMID]:24490384
[Au] Autor:Tang HX; Xiong XF; Qin ZQ
[Ad] Endereço:Heshan District Maternal and Child Health Hospital of Yiyang City in Hunan Province, Yiyang 413002, China.
[Ti] Título:[Clinical experience on treating Toxoplasma gondii infection during pregnancy by using acetyl spiramycin combined with azithromycin].
[So] Source:Zhongguo Xue Xi Chong Bing Fang Zhi Za Zhi;25(5):555-6, 2013 Oct.
[Is] ISSN:1005-6661
[Cp] País de publicação:China
[La] Idioma:chi
[Ab] Resumo:OBJECTIVE: To explore an effective therapy for pregnant Toxoplasma gondii infection by using acetyl spiramycin combined with azithromycin. METHODS: ELISA and PCR were used to diagnose and evaluate the therapy efficiency to toxoplasmosis in pregnant women. RESULTS: The serological test showed that the positive rates of specific antibodies IgM and IgG to Toxoplasma gondii in 285 pregnant women were 1.05% (3/285) and 5.97% (17/285), respectively. All the 3 cases of serum IgM positive pregnant women received the amniotic fluid PCR tests for Toxoplasma gondii DNA and 2 were positive, and they received spiramycin combined with azithromycin. After the therapy, their serum IgM antibody specific to Toxoplasma gondii and positive amniotic fluid PCR test for Toxoplasma gondii DNA turned to be negative. CONCLUSION: Acetyl spiramycin in combination with azithromycin is effective in the treatment of pregnant toxoplasmosis.
[Mh] Termos MeSH primário: Antibacterianos/administração & dosagem
Azitromicina/administração & dosagem
Leucomicinas/administração & dosagem
Complicações Parasitárias na Gravidez/tratamento farmacológico
Espiramicina/análogos & derivados
Toxoplasmose/tratamento farmacológico
[Mh] Termos MeSH secundário: Adolescente
Adulto
DNA de Protozoário/sangue
Quimioterapia Combinada
Feminino
Seres Humanos
Reação em Cadeia da Polimerase
Gravidez
Espiramicina/administração & dosagem
[Pt] Tipo de publicação:ENGLISH ABSTRACT; JOURNAL ARTICLE
[Nm] Nome de substância:
0 (Anti-Bacterial Agents); 0 (DNA, Protozoan); 0 (Leucomycins); 05298J5WMU (acetylspiramycin); 8025-81-8 (Spiramycin); 83905-01-5 (Azithromycin)
[Em] Mês de entrada:1405
[Cu] Atualização por classe:140204
[Lr] Data última revisão:
140204
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:140205
[St] Status:MEDLINE


  9 / 1699 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:23770781
[Au] Autor:Armenta S; Alcalà M; Blanco M; González JM
[Ad] Endereço:Department of Chemistry, Faculty of Sciences, Universitat Autònoma de Barcelona, E-08193 Bellaterra, Barcelona, Spain. sergio.armenta@uab.cat
[Ti] Título:Ion mobility spectrometry for the simultaneous determination of diacetyl midecamycin and detergents in cleaning validation.
[So] Source:J Pharm Biomed Anal;83:265-72, 2013 Sep.
[Is] ISSN:1873-264X
[Cp] País de publicação:England
[La] Idioma:eng
[Ab] Resumo:In the present paper, we have developed two different approaches based on ion mobility spectrometry (IMS) for the cleaning validation of diacetyl midecamycin in the surfaces of manufacture equipment: a semi-quantitative approach based on the use of a sample wand and a quantitative procedure based on the swab test. The simultaneous determination of the active pharmaceutical ingredient and cleaning agents has been performed without important effects of ionization suppression upon the analysis of swabs containing multiple components. Sensitivity, in the ng range, and appropriate selectivity ratify IMS as a serious alternative, a fast and serious alternative in cleaning validation. Other advantage imply its potential for at-line use to perform a semi-quantitative procedure using a sample wand which allows Teflon membranes, swabbed onto the stainless steel surfaces, to be introduced directly into the instrument with no dilution or extraction.
[Mh] Termos MeSH primário: Detergentes/química
Íons/química
Leucomicinas/química
Análise Espectral/métodos
[Mh] Termos MeSH secundário: Indústria Farmacêutica/métodos
Contaminação de Equipamentos
Aço Inoxidável/análise
[Pt] Tipo de publicação:JOURNAL ARTICLE; RESEARCH SUPPORT, NON-U.S. GOV'T
[Nm] Nome de substância:
0 (Detergents); 0 (Ions); 0 (Leucomycins); 12597-68-1 (Stainless Steel); N34Z0Y5UH7 (midecamycin)
[Em] Mês de entrada:1403
[Cu] Atualização por classe:171116
[Lr] Data última revisão:
171116
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:130618
[St] Status:MEDLINE


  10 / 1699 MEDLINE  
              first record previous record
seleciona
para imprimir
Fotocópia
PubMed Central Texto completo
Texto completo
[PMID]:23274670
[Au] Autor:Iizaka Y; Higashi N; Ishida M; Oiwa R; Ichikawa Y; Takeda M; Anzai Y; Kato F
[Ad] Endereço:Faculty of Pharmaceutical Sciences, Toho University, Funabashi, Chiba, Japan.
[Ti] Título:Function of cytochrome P450 enzymes RosC and RosD in the biosynthesis of rosamicin macrolide antibiotic produced by Micromonospora rosaria.
[So] Source:Antimicrob Agents Chemother;57(3):1529-31, 2013 Mar.
[Is] ISSN:1098-6596
[Cp] País de publicação:United States
[La] Idioma:eng
[Ab] Resumo:The cytochrome P450 enzyme-encoding genes rosC and rosD were cloned from the rosamicin biosynthetic gene cluster of Micromonospora rosaria IFO13697. The functions of RosC and RosD were demonstrated by gene disruption and complementation with M. rosaria and bioconversion of rosamicin biosynthetic intermediates with Escherichia coli expressing RosC and RosD. It is proposed that M. rosaria IFO13697 has two pathway branches that lead from the first desosaminyl rosamicin intermediate, 20-deoxo-20-dihydro-12,13-deepoxyrosamicin, to rosamicin.
[Mh] Termos MeSH primário: Antibacterianos/biossíntese
Proteínas de Bactérias/metabolismo
Sistema Enzimático do Citocromo P-450/metabolismo
Leucomicinas/biossíntese
Micromonospora/enzimologia
Micromonospora/genética
[Mh] Termos MeSH secundário: Proteínas de Bactérias/genética
Sistema Enzimático do Citocromo P-450/genética
Escherichia coli/enzimologia
Escherichia coli/genética
Deleção de Genes
Teste de Complementação Genética
Família Multigênica
[Pt] Tipo de publicação:JOURNAL ARTICLE
[Nm] Nome de substância:
0 (Anti-Bacterial Agents); 0 (Bacterial Proteins); 0 (Leucomycins); 9035-51-2 (Cytochrome P-450 Enzyme System); E907BNQ7SH (rosaramicin)
[Em] Mês de entrada:1307
[Cu] Atualização por classe:150219
[Lr] Data última revisão:
150219
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:130101
[St] Status:MEDLINE
[do] DOI:10.1128/AAC.02092-12



página 1 de 170 ir para página                         
   


Refinar a pesquisa
  Base de dados : MEDLINE Formulário avançado   

    Pesquisar no campo  
1  
2
3
 
           



Search engine: iAH v2.6 powered by WWWISIS

BIREME/OPAS/OMS - Centro Latino-Americano e do Caribe de Informação em Ciências da Saúde